Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 9/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | F2RL1 | P55085 | 2/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22645117 | 0.84 | KDM4E (0.46) | FPR2KDM4EALDH1A1MMP1MMP3 | |
| SCHEMBL6171373 | 0.83 | ALDH1A1 (0.42) | FPR2KDM4EALDH1A1MMP1MMP3 | |
| SCHEMBL27693248 | 0.81 | FPR2 (0.44) | FPR2KDM4EALDH1A1MMP1MMP3 | |
| SCHEMBL28626525 | 0.79 | FPR2 (0.43) | FPR2KDM4EALDH1A1MMP1MMP3 | |
| SCHEMBL570524 | 0.79 | ADRA2A (0.47) | FPR2KDM4EALDH1A1MMP1MMP3 | |
| SCHEMBL6448258 | 0.79 | FPR2 (0.43) | FPR2KDM4EALDH1A1MMP1MMP3 | |
| SCHEMBL5460567 | 0.78 | CSNK1A1 (0.44) | FPR2KDM4EALDH1A1MMP1MMP3 | |
| Hydrochloric Acid SCHEMBL28220351 | 0.78 | ADRA2A (0.46) | FPR2KDM4EALDH1A1MMP1MMP3 | |
| Bromide SCHEMBL28219788 | 0.78 | ADRA2A (0.46) | FPR2KDM4EALDH1A1MMP1MMP3 | |
| SCHEMBL4411652 | 0.77 | MMP1 (0.43) | FPR2KDM4EALDH1A1MMP1MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1111237-A | Preparation of amides and peptides | HOFFMANN LA ROCHE (CH) | 1995-11-08 | — | — | CN | claimed |
| US-8067453-B2 | Oxazole compound to treat or prevent diabetic neuropathy; 4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl-2-methyl-1-imidazolyl)oxazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20080269219-A1 | Neurotrophin production/secretion promoting agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-30 | — | — | US | disclosed |
| US-7396848-B1 | oxazole derivatives to treat diabetic neuropathy and/or other kinds of peripheral neuropathy; 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-08 | — | — | US | disclosed |
| CN-1291985-C | Neurotrophin production/secretion promoting agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2006-12-27 | — | — | CN | disclosed |
| EP-1206472-B1 | OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-10-01 | — | — | EP | disclosed |
| US-6605629-B1 | Oxazole derivatives; low toxicity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-12 | — | — | US | disclosed |
| CN-1372557-A | Neurotrophin production/secretion promoting agent | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-10-02 | — | — | CN | disclosed |
| EP-1206472-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT | Takeda Chemical Industries, Ltd. (JP) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001014372-A2 | OXAZOLE AND THIAZOLE DERIVATIVES AS NEUROTROPHIN PRODUCTION/SECRETION PROMOTING AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269219-A1 | Neurotrophin production/secretion promoting agent | BDNF, NGF, NTRK2 | FPR2 875/4885KDM4E 4507/4885ALDH1A1 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.